Method of use
View Patent ↗The present invention relates to a novel method of treatment of acne in a human patient in need thereof, comprising administering topically to said patient an effective amount of the compound 3,5-Dihydroxy-4-isopropyl-trans-stilbene (Compound 1) or a pharmaceutically acceptable salt thereof.
1. A method of treating acne in a human in need thereof comprising topically administering to said human an effective amount of a compound which is 3,5-Dihydroxy-4-isopropyl-trans-stilbene, or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein the acne is truncal acne.
3. The method according to claim 1 wherein acne lesions are affecting the facial and scalp areas of the human.
4. The method according to claim 1 wherein the compound is administered once daily to the affected areas of said human.
5. The method according to claim 1 wherein the compound is administered twice daily to the affected areas of said human.
6. The method according to claim 1 wherein the compound is 3,5-Dihydroxy-4-isopropy 1-trans-stilbene.
7. The method according to claim 1 wherein the compound is applied topically in a concentration ranging from 0.5% to 5% w/w.
8. The method according to claim 7 wherein the compound is applied topically in a concentration ranging from 0.5% to 2% w/w.
9. The method according to claim 8 wherein the compound is applied topically at 0.5%, 1%, or 2% w/w.
10. The method according to claim 1 wherein the compound is co-administered with an effective amount of a second therapeutic agent for the treatment of acne.
11. The method according to claim 10 wherein the co-administration of the second therapeutic agent is together at the same time, sequentially or contemporaneously with the 3,5-Dihydroxy-4-isopropyl-trans-stilbene, or a pharmaceutically acceptable salt thereof.
12. The method according to claim 11 wherein the 3,5-Dihydroxy-4-isopropyl-trans-stilbene, or a pharmaceutically acceptable salt thereof is administered at an alternative time to the second therapeutic agent.
13. A method of treating acne in a human in need thereof comprising topically administering to said human an effective amount of a pharmaceutical composition comprising 3,5-Dihydroxy-4-isopropyl-trans-stilbene, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
14. The method according to claim 13 wherein the acne is truncal acne.
15. The method according to claim 13 wherein acne lesions are affecting the facial and scalp areas of the human.
16. The method according to claim 13 wherein the compound is administered once daily to the affected areas of said human.
17. The method according to claim 13 wherein the compound is administered twice daily to the affected areas of said human.
18. The method according to claim 13 wherein the compound is 3,5-Dihydroxy-4-isopropy 1-trans-stilbene.
19. The method according to claim 13 wherein the compound is applied topically in a concentration ranging from 0.5% to 5% w/w.
20. The method according to claim 19 wherein the compound is applied topically in a concentration ranging from 0.5% to 2% w/w.
21. The method according to claim 20 wherein the compound is applied topically at 0.5%, 1%, or 2% w/w.
22. The method according to claim 13 wherein the compound is co-administered with an effective amount of a therapeutic agent for the treatment of acne.
23. The method according to claim 22 wherein the co-administration of the second therapeutic agent is together at the same time, sequentially or contemporaneously with the 3,5-Dihydroxy-4-isopropyl-trans-stilbene, or a pharmaceutically acceptable salt thereof.
24. The method according to claim 23 wherein the 3,5-Dihydroxy-4-isopropyl-trans-stilbene, or a pharmaceutically acceptable salt thereof is administered at an alternative time to the second therapeutic agent.
25. The method according to claim 10 wherein the second therapeutic agent is administered orally or topically.
26. The method according to claim 22 wherein the second therapeutic agent is administered orally or topically.
27. The method according to claim 10 wherein the second therapeutic agent is selected from the group consisting of benzoyl peroxide, azelaic acid, dapsone, salicylic acid, tretinoin, adapalene, clindamycin phosphate, clinamycin, lincomycin, retapamullin, mupirocin, fusidic acid, tetracycline, doxycycline, minocycline, tetracycline, penicillin, quinolone, fluoroquinolones, isotretinoin, and any derivatives thereof.
28. The method according to claim 22 wherein the second therapeutic agent is selected from the group consisting of benzoyl peroxide, azelaic acid, dapsone, salicylic acid, tretinoin, adapalene, clindamycin phosphate, clinamycin, lincomycin, retapamullin, mupirocin, fusidic acid, tetracycline, doxycycline, minocycline, tetracycline, penicillin, quinolone, fluoroquinolones, isotretinoin, and any derivatives thereof.
29. The method according to claim 1 wherein the compound is administered every other day, twice weekly, three times weekly, or once weekly.
30. The method according to claim 13 wherein the compound is administered every other day, twice weekly, three times weekly, or once weekly.